Zabofloxacin versus moxifloxacin in patients with COPD exacerbation: a multicenter, double-blind, double-dummy, randomized, controlled, Phase III, non-inferiority trial

A new quinolone, zabofloxacin, has now been developed; hence, a non-inferiority trial is needed to compare this new compound with another widely used quinolone to examine its efficacy and safety for the treatment of chronic obstructive pulmonary disease (COPD) exacerbations. This was a prospective,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Chron Obstruct Pulmon Dis
Main Authors: Rhee, Chin Kook, Chang, Jung Hyun, Choi, Eu gene, Kim, Hyun kuk, Kwon, Yong-Soo, Kyung, Sun Young, Lee, Ji-Hyun, Park, Myung Jae, Yoo, Kwang Ha, Oh, Yeon Mok
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2015
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4622522/
https://ncbi.nlm.nih.gov/pubmed/26543359
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S90948
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados